What is the share price of Vivanza Biosciences Ltd (VIVANZA) today?
The share price of VIVANZA as on 17th April 2025 is ₹2.34. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Vivanza Biosciences Ltd (VIVANZA) share?
The past returns of Vivanza Biosciences Ltd (VIVANZA) share are- Past 1 week: -2.50%
- Past 1 month: 10.90%
- Past 3 months: -30.56%
- Past 6 months: -37.93%
- Past 1 year: -72.63%
- Past 3 years: -87.60%
- Past 5 years: 87.95%
What are the peers or stocks similar to Vivanza Biosciences Ltd (VIVANZA)?
The peers or stocks similar to Vivanza Biosciences Ltd (VIVANZA) include:What is the market cap of Vivanza Biosciences Ltd (VIVANZA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Vivanza Biosciences Ltd (VIVANZA) is ₹9.34 Cr as of 17th April 2025.What is the 52 week high and low of Vivanza Biosciences Ltd (VIVANZA) share?
The 52-week high of Vivanza Biosciences Ltd (VIVANZA) is ₹8.60 and the 52-week low is ₹1.90.What is the PE and PB ratio of Vivanza Biosciences Ltd (VIVANZA) stock?
The P/E (price-to-earnings) ratio of Vivanza Biosciences Ltd (VIVANZA) is 16.98. The P/B (price-to-book) ratio is 2.01.Which sector does Vivanza Biosciences Ltd (VIVANZA) belong to?
Vivanza Biosciences Ltd (VIVANZA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Vivanza Biosciences Ltd (VIVANZA) shares?
You can directly buy Vivanza Biosciences Ltd (VIVANZA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Vivanza Biosciences Ltd
VIVANZA Share Price
2.340.43% (+0.01)
VIVANZA Share Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
VIVANZA Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
HighStrong financials and growth story over the years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
VIVANZA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -103.75 | 2.01 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 49.39 | 6.29 | 0.54% |
VIVANZA Analyst Ratings & Forecast
Detailed Forecast —
Forecast data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
VIVANZA Company Profile
Vivanza Biosciences is engaged in the business of trading of pharmaceutical products.
VIVANZA Similar Stocks (Peers)
Compare with peersSUNPHARMA
PE Ratio
43.78
1Y Return
15.50%
Buy Reco %
88.24
CIPLA
PE Ratio
29.62
1Y Return
12.46%
Buy Reco %
72.73
TORNTPHARM
PE Ratio
66.34
1Y Return
27.80%
Buy Reco %
68.00
MANKIND
PE Ratio
55.55
1Y Return
7.76%
Buy Reco %
81.25
DRREDDY
PE Ratio
17.34
1Y Return
2.34%
Buy Reco %
46.67
VIVANZA Forecasts
Price
Revenue
Earnings
VIVANZA Share Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeVIVANZA Company Revenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeVIVANZA Stock EPS (Earnings Per Share) Forecast
Hmm, looks like data is unavailable here. Please come back after some timeVIVANZA
Income
Balance Sheet
Cash Flow
Annual Normal View
VIVANZA Income Statement
Annual Normal View
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 3.52 | 6.44 | 2.66 | 10.19 | 10.40 | 11.23 | 18.29 | 27.89 | 11.34 | ||||||||||
Raw Materials | 0.00 | 4.88 | 6.00 | 2.08 | 8.26 | 8.84 | 11.43 | 16.55 | 25.48 | 10.91 | ||||||||||
| Power & Fuel Cost | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||
| Employee Cost | 0.00 | 0.38 | 0.09 | 0.05 | 0.30 | 0.34 | 0.25 | 0.31 | 0.45 | |||||||||||
| Selling & Administrative Expenses | 0.06 | 0.29 | 0.17 | 0.22 | 0.28 | 0.21 | 0.37 | 0.23 | 0.29 | |||||||||||
| Operating & Other expenses | 0.00 | -1.76 | -0.42 | 0.33 | 1.12 | 0.39 | -1.59 | 0.04 | 0.54 | |||||||||||
EBITDA | -0.06 | -0.27 | 0.60 | -0.02 | 0.23 | 0.62 | 0.77 | 1.16 | 1.13 | 0.43 | ||||||||||
| Depreciation/Amortization | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | ||||||||||
| PBIT | -0.06 | -0.27 | 0.60 | -0.02 | 0.23 | 0.61 | 0.76 | 1.16 | 1.12 | 0.42 | ||||||||||
| Interest & Other Items | 0.00 | 0.04 | 0.37 | 0.42 | 0.44 | 0.47 | 0.43 | 0.43 | 0.42 | 0.36 | ||||||||||
| PBT | -0.06 | -0.31 | 0.23 | -0.44 | -0.21 | 0.14 | 0.33 | 0.73 | 0.70 | 0.06 | ||||||||||
| Taxes & Other Items | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.05 | 0.00 | 0.12 | 0.15 | 0.15 | ||||||||||
| Net Income | -0.06 | -0.31 | 0.20 | -0.44 | -0.21 | 0.09 | 0.33 | 0.61 | 0.55 | -0.09 | ||||||||||
| EPS | -0.03 | -0.01 | 0.01 | -0.01 | -0.01 | 0.00 | 0.01 | 0.03 | 0.14 | -0.02 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
VIVANZA Company Updates
FY 2015
Annual report
PDFFY 2016
Annual report
PDFFY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2022
Annual report
PDFFY 2023
Annual report
PDFFY 2024
Annual report
PDFVIVANZA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Vivanza Biosciences Ltd | 16.98 | 2.01 | — |
| Sun Pharmaceutical Industries Ltd | 43.78 | 6.25 | 0.77% |
| Cipla Ltd | 29.62 | 4.55 | 0.86% |
| Torrent Pharmaceuticals Ltd | 66.34 | 16.03 | 0.86% |
VIVANZA Stock Price Comparison
Compare VIVANZA with any stock or ETFCompare VIVANZA with any stock or ETF
VIVANZA
VIVANZA Shareholdings
VIVANZA Promoter Holdings Trend
Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 19.84%
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
VIVANZA Institutional Holdings Trend
Increased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has increased by 3.40%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
VIVANZA Shareholding Pattern
VIVANZA Shareholding History
Foreign Institutions
smallcases containing VIVANZA stock
Looks like this stock is not in any smallcase yet.
VIVANZA Events
VIVANZA Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
VIVANZA has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
VIVANZA Dividends
Hmm, looks like data is unavailable here. Please come back after some timeVIVANZA Stock News & Opinions
Articles & Videos
Earnings
Vivanza Biosciences consolidated net profit declines 80.95% in the December 2024 quarter
Net profit of Vivanza Biosciences declined 80.95% to Rs 0.04 crore in the quarter ended December 2024 as against Rs 0.21 crore during the previous quarter ended December 2023. Sales declined 77.13% to Rs 1.50 crore in the quarter ended December 2024 as against Rs 6.56 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales1.506.56 -77 OPM %8.004.42 - PBDT0.050.21 -76 PBT0.040.21 -81 NP0.040.21 -81 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Vivanza Biosciences to discuss results
Vivanza Biosciences will hold a meeting of the Board of Directors of the Company on 31 January 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Vivanza Biosciences consolidated net profit declines 92.31% in the September 2024 quarter
Net profit of Vivanza Biosciences declined 92.31% to Rs 0.02 crore in the quarter ended September 2024 as against Rs 0.26 crore during the previous quarter ended September 2023. Sales declined 60.63% to Rs 3.00 crore in the quarter ended September 2024 as against Rs 7.62 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales3.007.62 -61 OPM %3.674.20 - PBDT0.020.26 -92 PBT0.020.26 -92 NP0.020.26 -92 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Vivanza Biosciences to declare Quarterly Result
Vivanza Biosciences will hold a meeting of the Board of Directors of the Company on 17 October 2024.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Vivanza Biosciences consolidated net profit declines 44.90% in the June 2024 quarter
Net profit of Vivanza Biosciences declined 44.90% to Rs 0.27 crore in the quarter ended June 2024 as against Rs 0.49 crore during the previous quarter ended June 2023. Sales declined 73.56% to Rs 2.44 crore in the quarter ended June 2024 as against Rs 9.23 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales2.449.23 -74 OPM %14.756.50 - PBDT0.270.49 -45 PBT0.270.49 -45 NP0.270.49 -45 Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Vivanza Biosciences to announce Quarterly Result
Vivanza Biosciences will hold a meeting of the Board of Directors of the Company on 8 August 2024.Powered by Capital Market - Live
8 months agoCapital Market - Live
Vivanza Biosciences consolidated net profit declines 34.62% in the September 2022 quarter
2 years agoBusiness Standard
Vivanza Biosciences consolidated net profit rises 23.81% in the September 2021 quarter
3 years agoBusiness Standard
Vivanza Biosciences reports consolidated net profit of Rs 0.32 crore in the June 2021 quarter
3 years agoBusiness Standard
Vivanza Biosciences reports consolidated net loss of Rs 0.13 crore in the March 2021 quarter
3 years agoBusiness Standard
Over the last 5 years, revenue has grown at a yearly rate of 60%, vs industry avg of 9.04%
Over the last 5 years, market share increased from 0% to 0.01%